Prospective cohort study of HCV patients
Case Study: Eradication of HCV Genotype 3 in 45 Years Old Male
A 45 year old white business man was first found to have abnormal biochemical liver tests in 2011. He went to see his physician for a checkup following his release from an orthopedic trauma surgery clinic where he was treated after a major car accident. He received blood transfusions during the treatment in the clinic. The patient was referred to a hepatologist after undergoing testing and was found positive for hepatitis C, genotype 3. The patient was unaware of acute infection due to its asymptomatic presentation. He felt well and denied any history of gastrointestinal bleeding, encephalopathy, or abdominal swelling; he occasionally drank in high excess. A non-invasive assessment of liver fibrosis with transient elastography (FibroScan) and the serological fibrosis marker FibroTest showed grade 1 activity and F2 fibrosis (METAVIR). He refused combined pegIFN and RBV therapy and in May 2011 was subsequently put on 20 mg daily dose of the probiotic glycopeptide ZL016. 18 weeks into the regimen, he was cleared of the virus and his transaminases returned to normal (see chart above). He continues taking ZL016 and performs regular checkups. He has remained virus free ever since. In 2015, three years after his first liver examination, he repeated FibroScan and FibroTest that revealed no signs of fibrosis.
Case Study: Viral Aplastic Aneamia
Clinical efects in cancer patients
Results published in Medical Oncology showed the significant clinical effects of glycopeptides, namely a prototype of ZL015 that mimics a peptidoglycan stem glycopeptide. A total of 63 patients in the terminal stages of various cancers were involved in those studies. All patients had received conventional treatment with chemotherapy and radiation. All of them suffered from cachexia and their blood tests revealed a 3 to10 fold increase in LDH activity for all five LDH isoenzymes; the activity of liver enzymes was also increased. PGN stem glycopeptide was given to 44 patients orally at a dosage of 0.5-1.5 mg/kg daily; 19 patients received a placebo. LDH activity was decreased by 40% in all 21 subjects who were given 0.5-1.0 mg/kg glycopeptide daily. In addition, LDH activity was lowered by 70% in 23 patients who received a1.5 mg/kg glycopeptide dose daily. Correspondingly, a 10% increase in LDH activity was noticed in 19 patients who were given a placebo. GGT activity was reduced by 35% in all seven patients, whose GGT level was measured. A drastic reduction in the level of triglycerides was noticed in all patients, as well as the reduction of the cholesterol level. During the follow-up period, the overall clinical condition of all patients treated with PGN glycopeptide was improved. Nine patients who experienced nausea from tumor toxicity before treatment noted symptoms subsiding after treatments. These studies demonstrated for the first time that glucosaminyl muramyl peptides could be powerful apoptosis modulators and antioxidants.